Last close As at 24/08/2026
—
— 0.00 (0.00%)
Market capitalisation
—
Research: Metals & Mining
For the second quarter in succession, Alphamin reported record revenue, operating profit, EBITDA, PBT and net profit. AISC was
| Year end | Revenue ($m) | PBT ($m) | EPS ($) | DPS (C$) | P/E (x) | Yield (%) |
|---|---|---|---|---|---|---|
| 12/24 | 528.0 | 203.0 | 0.08 | 0.09 | 13.0 | 6.3 |
| 12/25 | 620.9 | 280.6 | 0.12 | 0.11 | 8.9 | 7.6 |
| 12/26e | 1,010.6 | 581.4 | 0.21 | 0.26 | 4.8 | 18.1 |
| 12/27e | 597.0 | 248.4 | 0.10 | 0.15 | 10.3 | 10.4 |
Alphamin’s board is scheduled to consider its FY26 interim dividend in Q426. However,
if the tin price remains high, we believe that a repeat of the
Our discounted dividend valuation of Alphamin is
Alphamin’s Q226 financial results were released on 31 July, within the context of
operational results that had already been pre-released on 13 July, and they were nothing
if not striking, with revenue, operating profit, EBITDA, PBT and net profit all posting
records for the second quarter in succession, and attributable profit and EPS falling
fractionally short of posting new records on account of a slightly higher than normal
minority interest in percentage terms (owing to losses at the parent entity level
in which the ABM minorities did not share – major items in Q2 relating to dividend
withholding taxes and foreign exchange losses). All-in sustaining costs (AISC) remained
at higher levels, but no more so than expected, given the high tin price, which flows
through into selling costs and royalties. Nevertheless, while the AISC was
Although Alphamin’s net cash position declined by
The board is scheduled to consider the interim FY26 dividend in Q4. This followed
its decision at end-Q1 to make a final FY25 cash distribution of
Financially, revenue exceeded our prior forecast by
Exhibit 3, below, provides a comparison of Q226 results relative to our prior forecasts as well as our updated forecasts for the remainder of FY26, by quarter, in the light of Alphamin’s Q226 financial results:
As noted in our last report on Alphamin (see Tin closing in on
Alphamin’s board declared a final cash dividend of
In the 4½ years since it started making distributions therefore, Alphamin has returned
By historical standards, the
We do not know the board’s intentions regarding future dividends. However, we assume that it will be prudent in its payouts to shareholders. For the purposes of our valuation (below), we have initially assumed that the tin price remains high in FY26, but then falls back to long-term levels in FY27, in which the company’s super profit liability accrued in FY26 will also become payable. This would restrain the dividend potentially payable in FY27, although the board may wish to keep the actual dividend high, depending on its assessment of circumstances at the time. From FY28 we assume that all dividends that can be paid will be paid, to leave the company with zero net cash at the end of its assumed life in FY38. Variations from this ‘base case’ assumption are provided in the ‘Sensitivities’ section below.
Exploration continued in Q2, with a total of 3,654m drilled at Mpama South and 1,893m at Mpama North (in aggregate, an 18.7% increase relative to Q1).
Highlights of the three holes completed at Mpama North were:
Drilling at Mpama South in Q2 targeted extensions of the defined resource at depth. Five holes were completed, of which three intersected visible cassiterite mineralisation. Highlights included:
A cross-section of the areas being targeted by Alphamin is shown below:
One of Alphamin’s company objectives is to increase the intensity of its exploration to add to the current life of operations via drilling campaigns and focusing on grass-roots exploration in search of tin deposits in close proximity to the Bisie mine. In pursuit of this aim specifically, it has five initiatives currently underway:
Edison’s absolute valuation of single-asset mining companies is typically based on the value of dividends that a shareholder could expect to earn from their investment if they were to hold their shares from the moment of purchase until the end of the life of the mine, discounted to present value. Discretionary exploration investment is ordinarily excluded from the financial forecasts when this method is used, as it is presumed to be at least value adding. In practice therefore, the dividends in question are ‘maximum potential dividends’ (subject to assumptions about metals prices). However, the resulting net present value should be considered a conservative valuation since it omits the optionality of blue-sky exploration success during the operation of the mine. This method was typically used by the analyst community to value South African mines that were listed in London, such as Driefontein, Kloof, Vaal Reefs, Beatrix and Western Deep Levels, etc (albeit with different accounting practices), prior to 1995 when the South African mining house system of mine financing began to change.
Compared with the alternative discounted cash flow (DCF) method of analysis, the discounted dividend approach more purely reflects the returns that an equity shareholder may expect to receive. Hence, it is possible to calculate an internal rate of return (IRR) pertaining to an investment in a company’s equity at any particular share price and any particular point in time, rather than calculating an IRR for a project as a whole (which typically aggregates debt and equity returns and is therefore independent of a company’s share price). In its application it can also be made to naturally accommodate future equity dilution in calculating returns to shareholders. Being based on only one unit of measurement (forecast future dividends), it is also relatively simple to estimate a value (and hence share price) at some point in the future in contrast with a DCF valuation, which typically requires three inputs (namely, forecast future cash flows, net debt/cash and minority ownership). However, in the case of Alphamin, we have decided to present both discounted dividend and DCF valuations in order to benefit from the latter’s ability to generate a terminal cash flow multiple to accommodate potential mine life extensions.
Given our assumptions (above), we assume that FY26 will be an exceptional year in
terms of earnings and dividends, but there will be a return to normality in FY27.
As noted previously, under these circumstances, we expect the dividend to be restrained
in FY27, but then to rebound in FY28 when there is no longer any super profit liability
to be paid. For the eight years thereafter, we expect EPS to average
In this case, our discounted dividend valuation is almost exactly corroborated by
a discounted attributable cash flow valuation also of
Our cash flow and terminal multiple valuation methodology uses FY29 as its terminal
year, as it is representative of the cash flows per share that we estimate Alphamin
is capable of earning for the following seven years. Since it includes discretionary
exploration expenditure (which our discounted dividend and discounted cash flow valuations
do not), this approach yields a slightly lower valuation number of
A graph of our valuation of Alphamin as at 1 January 2026, given increasing operational life at Bisie with exploration success, is shown below:
In the meantime, at Alphamin’s current share price, our forecasts suggest a current year P/E ratio falling from 18.3x in FY23 (see also Exhibits 9 and 10) to 4.8x in FY26.
A comparison of Alphamin’s valuation relative to those of its peers, based on a series of commonly used prospective valuation multiples (where available), is provided below:
On this relative basis, Alphamin is priced at multiples that are cheaper than the
averages of its peers on 91% of valuation measures (ie 11 out of 12). On a discrete
basis, it is cheaper than its peers on 33 out of 41 (or 80%) of valuation measures.
Alternatively, we calculate that the average Alphamin share price implied by the average
multiples of its peers is
AFM has recorded positive EPS since FY21 and has paid out dividends since FY22. Since 2021, its average current year P/E ratio has been 11.2x, while its average (current year) dividend yield has been 6.7% (based on dividends paid in the period, rather than dividends paid for the period):
A summary of the share prices implied by AFM’s average historical P/E ratio of 11.2x current year earnings over the past five years, from FY21 to FY25 (inclusive), and its average historical yield of 6.7% from FY22 to FY25 (inclusive), as applied to Edison forecasts for FY26e to FY28e, is as follows:
By far Alphamin’s greatest valuation sensitivity is to the price of tin, which has
risen by over 50% in the past three quarters, from
Note that the relatively small valuation increase between a tin price of
Alphamin had net cash on its balance sheet of
General disclaimer and copyright
This report has been commissioned by Alphamin Resources and prepared and issued by Edison, in consideration of a fee payable by Alphamin Resources. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.
Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.
Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.
No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.
Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.
Copyright 2026 Edison Investment Research Limited (Edison).
Australia
Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.
New Zealand
The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.
United Kingdom
This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or sol icitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.
This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.
This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.
United States
Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.
London │ New York │ Frankfurt
20 Red Lion Street
London, WC1R 4PS
United Kingdom
Research: Healthcare
Percheron Therapeutics’ update for the quarter to 30 June confirmed that Phase II preparations for HMBD-002 (provisional name: minperstobart) remain on track. GMP drug substance manufacture is complete and final drug product is expected to be released in September 2026, supporting our Q4 CY26 Phase II initiation assumption. The A$2.2m entitlement offer lifted the end-Q2 CY26 cash to A$4.05m (end-Q1 CY26: A$3.10m), modestly ahead of our A$3.8m estimate. Quarterly operating cash burn was A$1.05m, including R&D expenses of A$0.43m. While the company reports a 3.9-quarter runway based on the pre-trial expenditure rate, this excludes the remaining